Question: What Swiss multinational healthcare company, introduced the steroidal progestin, Trengestone, in 1974?
Context: Norgestomet (INN, USAN, BAN) (brand name Syncro-Mate B; former developmental code name SC-21009), or norgestamet, also known as 11β-methyl-17α-acetoxy-19-norprogesterone, is a steroidal progestin of the 19-norprogesterone group used in veterinary medicine to control estrus and ovulation in cattle.  It was developed and introduced in the mid-1970s.  In addition to the progesterone receptor, norgestomet possesses weak (micromolar) affinity for the glucocorticoid receptor. Nomegestrol (INN), also known as 19-normegestrol, is a steroidal progestin which was patented in 1975 but was never marketed.  It is the parent compound of nomegestrol acetate, which is marketed as a progestin. Cismadinone acetate, also known as 6α-chloro-17α-acetoxypregna-1,4-diene-3,20-dione or 6α-chloro-δ-dehydro-17α-acetoxyprogesterone, is a steroidal progestin related to the 17α-hydroxyprogesterone derivatives that was never marketed.  It is the acetylated form of cismadinone, which is also a progestin but, similarly to cismadinone acetate, was never marketed. Trengestone (INN) (brand names Reteroid, Retroid, Retrone; former developmental code name Ro 4-8347), also known as 6-chloro-6,7-didehydroretroprogesterone or 6-chloro-9β-10α-pregna-1,4,6-triene-3,20-dione, is a steroidal progestin of the retroprogesterone group related to dydrogesterone that was formerly used to treat menstrual disorders.  It was synthesized in 1964 and was introduced for medical use by Roche in 1974. Dydrogesterone (INN, USAN, BAN) (brand name Duphaston), also known as isopregnenone or 6-dehydroretroprogesterone, as well as 9β,10α-pregna-4,6-diene-3,20-dione, is a steroidal progestin of the retroprogesterone group that was developed in the 1950s and introduced for clinical use in 1961.  It is available widely throughout Europe, including the United Kingdom and many other European countries, and is also marketed in Australia, Hong Kong, and India.  The drug was previously marketed in the United States as well, but is now no longer available in this country. F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.  Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.  The company headquarters are located in Basel. Pentagestrone acetate (brand names Gestovis, Gestovister), also known as 17α-acetoxyprogesterone 3-cyclopentyl enol ether, is a steroidal progestin of the 17α-hydroxyprogesterone group that was described in the literature in 1960 and introduced by Vister in Italy in 1961.  It is the 3-cyclopentyl enol ether of 17α-hydroxyprogesterone acetate.  Pentagestrone acetate, along with quingestrone (the 3-cyclopentyl enol ether of progesterone), is said to have very similar properties to those of dydrogesterone, a pure progestogen and close analogue of progesterone. Noretynodrel, or norethynodrel, is a steroidal progestin of the 19-nortestosterone group and an isomer of norethisterone.  Noretynodrel was introduced in 1957 in Enovid, a combination formulation of noretynodrel and mestranol, for the treatment of gynecological and menstrual disorders.  A few years later, in May 1960, Enovid was also approved as the first oral contraceptive. Demegestone (INN) (brand name Lutionex), also known as 17α-methyl-Δ-19-norprogesterone or 17α-methyl-19-norpregna-4,9-diene-3,20-dione, is a steroidal progestin of the 19-norprogesterone group which was introduced by Roussel in France in 1974.  Like other 19-norprogesterone derivatives, it has relatively high affinity for the progesterone receptor and shows little or no activity at other steroid hormone receptors. Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-Δ-19-norprogesterone or 17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione, is a steroidal progestin of the 19-norprogesterone group which was introduced in 1983 and is marketed in France, Portugal, and Argentina.  Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome.  Promegestone has weak glucocorticoid activity, but does not bind to the androgen receptor or possess antimineralocorticoid activity.  In addition, promegestone has been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor, similarly to progesterone.  The drug is mainly bound to albumin; it does not bind to sex hormone-binding globulin, and binds only weakly to transcortin.
Answer: Hoffmann-La Roche